March 6, 2014 Below is a pdf for MTSL Issue #774 of the Medical Technology Stock Letter.
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
Tag: NKTR
Nektar Update (11-16-12)
Nektarâs stock has had a horrible two weeks despite announcing positive top-line results from two Phase III trials and one safety extension trial in patients with non-cancer related pain and opioid-induced constipation (OIC). Last week, potential FDA concerns with CV risk associated with opioid withdrawal in chronic use of opioid antagonists became an investor issue[…]
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
Nektar Update (9-26-13)
Nektar’s NKTR-181 Disappoints, Misses Primary Endpoint on Mixed Phase II Data – Preliminary top-line results from a Phase II trial of NKTR-181(‘181) for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis of the knee missed their primary endpoint due to a unusual lack of a placebo rebound. The drug candidate was shown to[…]
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
Nektar Update (1-18-13)
CONTINUED PROGRESS AND PIPELINE VISIBILITY. Nektar management continues to make progress across its lateâstage development pipeline, relieving some investor concern for the naloxegol (NKTR-118) program â NKTRâs lead compound â under development for the treatment of opioid-induced constipation (OIC). With renewed optimism on the â118 program and upcoming related catalysts, increasing appreciation of the breadth[…]
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.